TakeAim
TakeAim Leukemia: A Phase 1/2A, Open Label Dose Escalation and Expansion Study of Orally Administered CA-4948 as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome and in Combination With Azacitidine or Venetoclax
Arms / Cohorts
Experimental:Dose Escalation: Emavusertib (CA-4948)
Accepting patients
Experimental:Dose Escalation: Emavusertib + Azacitidine
Accepting patients
Experimental:Dose Escalation: Emavusertib + Venetoclax
Accepting patients
Experimental:Dose Expansion: Emavusertib
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.